| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
EDUCATION EXHIBIT |
1 From the Division of Nuclear Medicine, Long Island Jewish Medical Center, 270-05 76th Ave, New Hyde Park, NY 11040. Presented as an education exhibit at the 2001 RSNA scientific assembly. Received May 28, 2002; revision requested July 24 and received August 19; accepted August 19. Address correspondence to C.L. (e-mail: love@lij.edu).
Bone scintigraphy with technetium-99m–labeled diphosphonates is one of the most frequently performed of all radionuclide procedures. Radionuclide bone imaging is not specific, but its excellent sensitivity makes it useful in screening for many pathologic conditions. Moreover, some conditions that are not clearly depicted on anatomic images can be diagnosed with bone scintigraphy. Bone metastases usually appear as multiple foci of increased activity, although they occasionally manifest as areas of decreased uptake. Traumatic processes can often be detected, even when radiographic findings are negative. Most fractures are scintigraphically detectable within 24 hours, although in elderly patients with osteopenia, further imaging at a later time is sometimes indicated. Athletic individuals are prone to musculoskeletal trauma, and radionuclide bone imaging is useful for identifying pathologic conditions such as plantar fasciitis, stress fractures, "shin splints," and spondylolysis, for which radiographs may be nondiagnostic. A combination of focal hyperperfusion, focal hyperemia, and focally increased bone uptake is virtually diagnostic for osteomyelitis in patients with nonviolated bone. Bone scintigraphy is also useful for evaluating disease extent in Paget disease and for localizing avascular necrosis in patients with negative radiographs. Radionuclide bone imaging will likely remain a popular and important imaging modality for years to come.
© RSNA, 2003
Index Terms: Bone neoplasms, secondary, 40.33 • Bones, infection, 40.21 • Bones, radionuclide studies, 40.1216, 40.12172 • Radionuclide imaging, 40.1216, 40.12172 • Reflex sympathetic dystrophy, 40.565 • Spondylolysis, 30.42 • Trauma, 40.41
This article has been cited by other articles:
|
|
 |
|
  K. Strobel, C. Burger, B. Seifert, D. B. Husarik, J. D. Soyka, and T. F. Hany Characterization of Focal Bone Lesions in the Axial Skeleton: Performance of Planar Bone Scintigraphy Compared with SPECT and SPECT Fused with CT Am. J. Roentgenol., May 1, 2007; 188(5): W467 - W474. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ogawa, T. Mukai, Y. Inoue, M. Ono, and H. Saji Development of a Novel 99mTc-Chelate-Conjugated Bisphosphonate with High Affinity for Bone as a Bone Scintigraphic Agent J. Nucl. Med., December 1, 2006; 47(12): 2042 - 2047. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Frater, D. Vu, H. Van der Wall, C. Perera, P. Halasz, L. Emmett, and I. Fogelman Bone Scintigraphy Predicts Outcome of Steroid Injection for Plantar Fasciitis J. Nucl. Med., October 1, 2006; 47(10): 1577 - 1580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Barragan-Campos, J.-N. Vallee, D. Lo, E. Cormier, B. Jean, M. Rose, P. Astagneau, and J. Chiras Percutaneous Vertebroplasty for Spinal Metastases: Complications Radiology, January 1, 2006; 238(1): 354 - 362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Utsunomiya, S. Shiraishi, M. Imuta, S. Tomiguchi, K. Kawanaka, S. Morishita, K. Awai, and Y. Yamashita Added Value of SPECT/CT Fusion in Assessing Suspected Bone Metastasis: Comparison with Scintigraphy Alone and Nonfused Scintigraphy and CT Radiology, December 1, 2005; 238(1): 264 - 271. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| RADIOGRAPHICS | RADIOLOGY | RSNA JOURNALS ONLINE |
